Clinical Trials Logo

Transplantation, Homologous clinical trials

View clinical trials related to Transplantation, Homologous.

Filter by:
  • None
  • Page 1

NCT ID: NCT00899847 Completed - Multiple Myeloma Clinical Trials

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Start date: May 2009
Phase: Phase 2
Study type: Interventional

To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant approach for patients with advanced stage multiple myeloma.

NCT ID: NCT00670423 Completed - Clinical trials for Graft vs Host Disease

A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation

Start date: May 16, 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is determine the highest dose of bortezomib, a new drug for graft-versus host disease prevention, that can be given in combination with sirolimus and Tacrolimus, without causing severe side effects. This research is being done because there is no treatment that is 100% effective in preventing graft versus host disease. The goals of this study are to: 1. Collect peripheral blood stem cells (PBSCs) from donors for transplant. 2. Determine the largest possible dose of bortezomib that can be given to recipients with various blood cancers in a safe manner. 3. Monitor the recipient for risk of infection or side affects associated with the transplant. 4. Monitor the recipient for increased immunity following transplantation.

NCT ID: NCT00008801 Active, not recruiting - Clinical trials for Diabetes Mellitus, Insulin-Dependent

hOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft Failure

Start date: n/a
Phase: Phase 1/Phase 2
Study type: Interventional

The broad, long-term goal of this proposal is to improve the results and applicability of islet allotransplantation early in the course of type 1 diabetes through the administration of selective and short-term immunotherapy. More specifically, the objectives of these studies is to conduct an open-labeled, one-year follow-up Phase I/II study in patients with surgical and type 1 diabetes to determine the safety, tolerability, immune activity, and pharmacokinetics of hOKT3gamma1 (Ala-ala) administration for the prevention of autoimmune destruction and rejection of allogeneic islet transplants.